GlaxoSmithKline plc (LON:GSK) received a GBX 1,500 ($19.73) price target from S&P Global in a research note issued to investors on Thursday, October 26th. The firm currently has a “neutral” rating on the stock. S&P Global’s target price indicates a potential upside of 13.81% from the company’s current price.
A number of other research analysts also recently issued reports on GSK. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($24.99) price objective on GlaxoSmithKline plc and gave the company a “buy” rating in a research note on Tuesday, August 8th. Deutsche Bank AG set a GBX 1,610 ($21.18) price target on GlaxoSmithKline plc and gave the stock a “neutral” rating in a research note on Tuesday, August 8th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline plc in a research note on Thursday, September 21st. Shore Capital restated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Wednesday, September 20th. Finally, Berenberg Bank cut their target price on GlaxoSmithKline plc from GBX 1,885 ($24.79) to GBX 1,835 ($24.14) and set a “buy” rating for the company in a research note on Wednesday, August 9th. Three investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of GBX 1,574.25 ($20.71).
GlaxoSmithKline plc (LON GSK) traded down GBX 28.50 ($0.37) during trading hours on Thursday, hitting GBX 1,318 ($17.34). The stock had a trading volume of 8,310,264 shares, compared to its average volume of 9,540,000. GlaxoSmithKline plc has a 52 week low of GBX 1,315.50 ($17.30) and a 52 week high of GBX 1,724.50 ($22.68).
GlaxoSmithKline plc (LON:GSK) last issued its earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.43) earnings per share for the quarter, topping analysts’ consensus estimates of GBX 31.80 ($0.42) by GBX 0.70 ($0.01). The company had revenue of GBX 784.30 billion for the quarter. GlaxoSmithKline plc had a return on equity of 461.88% and a net margin of 17.79%.
ILLEGAL ACTIVITY WARNING: This report was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2017/11/12/glaxosmithkline-plc-gsk-given-a-gbx-1500-price-target-by-sp-global-analysts.html.
In related news, insider Urs Rohner acquired 473 shares of GlaxoSmithKline plc stock in a transaction on Wednesday, October 25th. The stock was acquired at an average price of GBX 1,518 ($19.97) per share, for a total transaction of £7,180.14 ($9,443.82). Also, insider Simon Dingemans acquired 1,076 shares of GlaxoSmithKline plc stock in a transaction on Thursday, October 12th. The shares were bought at an average price of GBX 1,527 ($20.08) per share, with a total value of £16,430.52 ($21,610.57). Insiders have acquired a total of 1,576 shares of company stock worth $2,400,376 in the last ninety days.
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.